GNRH1 and posterior cortical atrophy: To overcome this phenomenon, degarelix was developed as a novel GnRH antagonist, with evidence supporting its effectiveness in maintaining testosterone levels below the castration levels in PCa patients, as reported in the CS21 study [3].